Donor T-cell-derived GM-CSF drives alloantigen presentation by dendritic cells in the gastrointestinal tract.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
08 10 2019
Historique:
received: 20 02 2019
accepted: 22 08 2019
entrez: 6 10 2019
pubmed: 6 10 2019
medline: 10 9 2020
Statut: ppublish

Résumé

Granulocyte-macrophage colony-stimulating factor (GM-CSF) has recently emerged as an important pathogenic cytokine in acute graft-versus-host disease (GVHD), but the nature of the T-cell lineages secreting the cytokine and the mechanisms of action are less clear. Here we used interleukin 17A-fate reporter systems with transcriptional analysis and assays of alloantigen presentation to interrogate the origins of GM-CSF-secreting T cells and the effects of the cytokine on antigen-presenting cell (APC) function after experimental allogeneic stem cell transplantation (SCT). We demonstrated that although GM-CSF-secreting Th17 and non-Th17 cells expanded in the colon over time after SCT, the Th17 lineage expanded to represent 10% to 20% of the GM-CSF secreting T cells at this site by 4 weeks. Donor T-cell-derived GM-CSF expanded alloantigen-presenting donor dendritic cells (DCs) in the colon and lymph nodes. In the mesenteric lymph nodes, GM-CSF-dependent DCs primed donor T cells and amplified acute GVHD in the colon. We thus describe a feed-forward cascade whereby GM-CSF-secreting donor T cells accumulate and drive alloantigen presentation in the colon to amplify GVHD severity. GM-CSF inhibition may be a tractable clinical intervention to limit donor alloantigen presentation and GVHD in the lower gastrointestinal tract.

Identifiants

pubmed: 31585949
pii: bloodadvances.2019000053
doi: 10.1182/bloodadvances.2019000053
pmc: PMC6784518
doi:

Substances chimiques

Isoantigens 0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2859-2865

Informations de copyright

© 2019 by The American Society of Hematology.

Références

Blood. 2016 Aug 11;128(6):794-804
pubmed: 27338097
J Clin Invest. 2016 Sep 1;126(9):3541-55
pubmed: 27500496
Nat Med. 2011 Nov 29;18(1):135-42
pubmed: 22127134
Nat Immunol. 2011 Mar;12(3):255-63
pubmed: 21278737
Science. 1994 Apr 29;264(5159):713-6
pubmed: 8171324
Blood. 2009 May 28;113(22):5644-9
pubmed: 19336758
Blood. 2009 Jan 22;113(4):945-52
pubmed: 18931341
Immunol Rev. 2012 Nov;250(1):277-302
pubmed: 23046136
Blood. 2012 Jun 14;119(24):5918-30
pubmed: 22415754
Nat Immunol. 2014 Apr;15(4):373-83
pubmed: 24584090
Eur J Immunol. 2019 Jan;49(1):179-191
pubmed: 30457669
Blood. 2015 Sep 24;126(13):1609-20
pubmed: 26206951
JCI Insight. 2017 Jun 15;2(12):null
pubmed: 28614794
Blood. 2016 Jun 16;127(24):2963-70
pubmed: 27030390
J Exp Med. 2011 May 9;208(5):1069-82
pubmed: 21536742
Sci Transl Med. 2018 Nov 28;10(469):
pubmed: 30487251
J Immunol. 2012 Aug 15;189(4):1765-72
pubmed: 22778391
J Clin Invest. 2018 Mar 1;128(3):916-930
pubmed: 29376889
J Exp Med. 2015 Jul 27;212(8):1303-21
pubmed: 26169940
Blood Adv. 2017 Jan 26;1(6):341-351
pubmed: 29296949
Haematologica. 2016 Mar;101(3):e77-80
pubmed: 26589916
Nat Methods. 2012 Feb 26;9(4):385-90
pubmed: 22367054
Nat Rev Immunol. 2013 Jul;13(7):499-509
pubmed: 23787991
Am J Transplant. 2018 Apr;18(4):810-820
pubmed: 28941323
Nat Immunol. 2017 May;18(5):563-572
pubmed: 28346410
JCI Insight. 2018 Aug 23;3(16):
pubmed: 30135313
Blood. 2010 Nov 11;116(19):3955-63
pubmed: 20682855
J Clin Invest. 2014 Oct;124(10):4266-80
pubmed: 25157821
Cell. 2006 Sep 22;126(6):1121-33
pubmed: 16990136

Auteurs

Kate H Gartlan (KH)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Motoko Koyama (M)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Katie E Lineburg (KE)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Karshing Chang (K)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Kathleen S Ensbey (KS)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Rachel D Kuns (RD)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Andrea S Henden (AS)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Luke D Samson (LD)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

Andrew D Clouston (AD)

Envoi Specialist Pathologists, Brisbane, QLD, Australia.

Angel F Lopez (AF)

Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, SA, Australia; and.

Kelli P A MacDonald (KPA)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Geoffrey R Hill (GR)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Division of Medical Oncology, University of Washington, Seattle, WA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH